Carlos Marafusta
About Carlos Marafusta
Carlos Marafusta serves as the Senior Portuguese Country Manager at Wep Clinical, a position he has held since 2019. He has extensive experience in the pharmaceutical industry, having previously worked at AstraZeneca, Pfizer, and Bristol-Myers Squibb.
Work at WEP Clinical
Carlos Marafusta has been with WEP Clinical since 2018, where he currently serves as the Business Development Director for Europe. In this role, he focuses on expanding the company's presence and operations in the European market. Additionally, he has held the position of Senior Portuguese Country Manager since 2019, overseeing initiatives specifically tailored to the Portuguese market. His work involves strategic planning and collaboration with various stakeholders to enhance service delivery.
Previous Experience in the Pharmaceutical Industry
Carlos Marafusta has extensive experience in the pharmaceutical sector. He worked at AstraZeneca as an Area Manager from 2002 to 2005 in Cambridge, UK. Following this, he served as a Sales Representative at Pfizer from 2006 to 2007 in New York, USA. He also held the position of Healthcare Manager at Bristol-Myers Squibb from 2007 to 2008 in New Jersey, USA. His career includes a role as Director Comercial at Alkidok from 2010 to 2011.
Education and Expertise
Carlos Marafusta studied at Ipam, where he gained foundational knowledge that supports his career in business development and management within the pharmaceutical industry. His educational background complements his extensive professional experience, enabling him to navigate complex market dynamics effectively.
Career Timeline
Carlos Marafusta's career spans several key roles in the pharmaceutical industry. He began as an Area Manager at AstraZeneca from 2002 to 2005, followed by a position at Pfizer as a Sales Representative from 2006 to 2007. He then worked as a Healthcare Manager at Bristol-Myers Squibb from 2007 to 2008. After a brief tenure at Alkidok as Director Comercial from 2010 to 2011, he joined WEP Clinical in 2018, where he has since held two significant roles.